CF
GALT icon

Corebridge Financial’s Galectin Therapeutics GALT Stock Holding History

Corebridge Financial’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,402
Closed -$5.37K – 1068
2025
Q1 		$5.37K Sell
4,402
-5,722
-57% -$8.03K ﹤0.01% 2998
2024
Q4 		$13.1K Sell
10,124
-764
-7% -$1.83K ﹤0.01% 2993
2024
Q3 		$29.9K Sell
10,888
-67
-0.6% -$165 ﹤0.01% 2951
2024
Q2 		$24.9K Buy
+10,955
New +$33.3K ﹤0.01% 2972

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Corebridge Financial's GALT Position: Q2 2025 in Review

Corebridge Financial sold out of Galectin Therapeutics (GALT) in Q2 2025, closing a stake of 4,402 shares — an estimated $5.37K sold.

Corebridge Financial first reported a position in GALT in Q2 2024 and held it in 4 quarters. The position peaked at $29.9K in Q3 2024. 86 funds tracked by Wall St. Rank hold GALT as of Q2 2025.

  • Corebridge Financial reported no remaining Galectin Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 4,402 Galectin Therapeutics shares in Q2 2025, an estimated $5.37K.
  • Corebridge Financial first reported a position in Galectin Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Galectin Therapeutics position peaked at $29.9K in Q3 2024.
  • 86 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.